[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"CellEra LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":141},{"warningLetters":4,"total":140},[5,33,58,82,103,121],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":11,"recipient_name":29,"body_fetched_at":30,"delivery_method":31,"recipient_title":20,"reference_number":20,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},3052,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2021-11-02T13:20:00Z\">11\u002F02\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-20T04:00:00Z\">10\u002F20\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcellera-llc-618209-10202021\">CellEra LLC\u003C\u002Fa>","Office of Medical Device and Radiological Health Division 1 – East","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcellera-llc-618209-07212022\">\u003Ctime datetime=\"2022-07-25T04:00:00Z\">07\u002F25\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Richard E. Moon\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Financial Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>CellEra LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1045 Reed Dr, Ste C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Monroe\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>45050\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Device and Radiological Health Division 1 – East\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 618209\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 20, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Moon:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at CellEra LLC, located at 1045 Reed Dr, Ste C, Monroe, OH 45050, from June 16 through July 8, 2021. During the inspection, FDA investigators determined that your firm is a specification developer and own label distributor of various sterile wound dressings with drug. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response, dated July 30, 2021 from Ken Heyl, Chief Product Officer, concerning our investigators’ observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued on July 8, 2021. We address the response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures for implementing corrective and preventive actions and the failure to document corrective and preventive activities, as required by 21 CFR § 820.100.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm does not have a written corrective and preventive action procedure and has failed to document your firm’s corrective actions.\u003C\u002Fp>\n\n\u003Cp>For example, your firm made changes to your Instructions for Use (IFUs) of your sterile Vitále Silver Calcium Alginate wound dressing as a correction to the findings in the previous inspection ending 05\u002F31\u002F2019. However, your firm failed to implement this change and IFUs reviewed during the current inspection still include the following, which are claims not cleared in \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cp>• The term “antimicrobial” was not changed to “antibacterial”\u003Cbr>\n• The statement “The silver-impregnated calcium alginate fibers, when in contact with wound exudate or blood, form a gel which creates a moist wound healing environment. The silver has an antimicrobial effect within the dressing upon various types of microorganisms including Staphylococcus Aureus and Escherichia Coli”.\u003Cbr>\n• The description of “Superficial or Deep” for wound-type.\u003Cbr>\n• The instruction “cleanse the wound with Vitále Cleanser Spray or physiological saline solution.”\u003C\u002Fp>\n\n\u003Cp>None of your firm’s corrective action activities, including a report of corrective and removal (Z-2085-2019 \u002F RES# 83281) that was reported to the Agency, were documented.\u003C\u002Fp>\n\n\u003Cp>This is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude it is not adequate. Your response did not address the creation of a procedure for CAPA activities or your plan to document corrective and preventive actions.\u003C\u002Fp>\n\n\u003Cp>Further, you provided an updated IFU for the Vitále Silver Calcium Alginate Dressings via email on July 30, 2021. However, you have not provided objective evidence that this new IFU has been approved, the date when the IFU will be included with Vitále Silver Calcium Alginate Dressings, your plan to address the devices currently on the market or ready for distribution that contain an IFU with language beyond what was originally cleared by the Agency under \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Further, your response did not address initiating a CAPA(s) for the above IFU changes.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish and maintain procedures to control the design of the device, as required by 21 CFR § 820.30.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has failed to establish design controls that include adequate procedures for design inputs, design outputs, design verifications, design validations, design reviews, design transfers, design changes and the establishment of a design history file.\u003C\u002Fp>\n\n\u003Cp>This is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude it is not adequate. You do not address the establishment of procedures to control the design of devices developed by your firm. In your response, please provide your firm’s plan to address the lack of design control procedures and establishment of a design history file.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR § 820.30(i).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm indicated to our investigator that an estimated \u003Cstrong>(b)(4)\u003C\u002Fstrong> design changes have been made by your firm in the past \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Some of these design changes include changes to the IFUs for the Vitále Silver Calcium Alginate Dressings beyond the language cleared under \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the storage requirements for the Vitále Silver Calcium Alginate Dressings from \"Keep from Heat\" “below 77°F” to “41°F \u002F 5°C – 104°F \u002F 40°C”, a change to the sterilization method from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and a change to the shelf life of the Vitále Silver Calcium Alginate Ropes &amp; Dressings from 2 years to 3 years. These design changes have been made without documentation to include validation, verification, review, and approval prior to implementation.\u003C\u002Fp>\n\n\u003Cp>This is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and conclude it is not adequate. Your response indicated that you have drafted a form to use to make changes in products. Your response is not adequate because the “Product Change Request\u002FApproval” form does not include the requirement or allow for documentation of validation, verification (where appropriate), or review of the design change prior to approval. Additionally, you did not provide a retrospective review of design changes your firm has conducted to ensure design change requirements have been met.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements as required by 21 CFR § 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm failed to develop purchasing control procedures and has not established and maintained the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants.\u003C\u002Fp>\n\n\u003Cp>For example, your firm utilizes \u003Cstrong>(b)(4)\u003C\u002Fstrong> contract manufacturers to manufacture the products distributed by your firm. There is no agreement(s) in place that the contract manufacturers agree to notify your firm of changes in the product so your firm can determine whether the changes may affect the quality of a finished device. The storage requirements, sterilization method, and shelf life were changed by the contract manufacturer of your Vitále Silver Calcium Alginate Ropes &amp; Dressings without your firm’s knowledge or approval.\u003C\u002Fp>\n\n\u003Cp>This is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and conclude it is not adequate. Your response indicated that a procedure would be provided by September 8, 2021. To date, a procedure has not been received. Further, your response does not mention how your firm intends to define the type and extent of control to be exercised over contract manufacturers of your products from making changes or if you intend to create an agreement to be notified of changes in products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish and maintain procedures for acceptance of incoming product. Incoming product shall be inspected, tested, or otherwise verified as conforming to specified requirements as required by 21 CFR § 820.80(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm failed to develop procedures for acceptance of incoming product nor does your firm perform any activities related to the acceptance of incoming product other than a visual inspection for noticeable damage to the shipping boxes and device cartons. For example, you stated that sterility certificates received from your contract manufacturers are simply filed and not reviewed.\u003C\u002Fp>\n\n\u003Cp>This is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and conclude it is not adequate. Your response indicated that a procedure would be provided by September 8, 2021. To date, a procedure has not been received.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR § 820.198.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm failed to developed procedures for the receipt, review, and evaluation of complaints. For example, your firm receives oral complaints, but no record is made. Complaints received via your firm’s website are maintained in email format without any indication of evaluation by your firm.\u003C\u002Fp>\n\n\u003Cp>This is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and conclude it is not adequate. Your response indicated that your plan to have a formally designated unit to handle complaints and a procedure to follow. This response also indicated that no procedure finish date has been established. To date, a procedure or anticipated date of completion have not been received.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish and maintain procedures to control all documents as required by 21 CFR § 820.40.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and conclude it is not adequate. Your response did not address the corrective actions you plan to take. It is unclear if your firm plans to create a document control procedure.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish and maintain procedures to adequately control environmental conditions, where environmental conditions could reasonably be expected to have an adverse effect on product quality. Environmental control system(s) shall be periodically inspected to verify that the system, including necessary equipment, is adequate and functioning properly. These activities shall be documented and reviewed as required by 21 CFR § 820.70(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm’s Vitále Silver Calcium Alginate Dressings and Ropes, which are sterile medical devices, have specific temperature storage requirements. Your firm has not developed procedures to adequately control the environmental conditions needed to maintain the environmental requirements, to including storage temperatures, for your devices.\u003C\u002Fp>\n\n\u003Cp>This is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and conclude it is not adequate. Your response indicated that you plan to draft a procedure with a deadline of January 31, 2022. In your response, please provide an explanation why this procedure will take until January 31, 2022 to be established. Additionally, please explain how your firm intends to verify that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature and humidity sensors currently in use at your firm are adequate and functioning properly.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your Vitále Silver Calcium Alginate Dressings and Ropes are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation includes, but is not limited to:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and conclude it is not adequate. In the response, your firm noted you plan to develop these procedures but have not established a date to develop the procedure.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned\u003Cbr>\ncorrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding any issues in this letter, please contact Compliance Officer, Sean Moynihan at 410-779-5134 or at sean.moynihan@fda.hhs.gov. Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Arduino Frankovic\u003Cbr>\nActing Program Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 1 – East\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>Ken Heyl\u003Cbr>\nChief Product Officer\u003Cbr>\n2044 Grove Park Way\u003Cbr>\nBirmingham, AL 35242\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRichard E. Moon\n\nRecipient Title\n\nChief Financial Officer\n\nCellEra LLC\n\n1045 Reed Dr, Ste C\n\nMonroe, OH 45050\n\nUnited States\n\nIssuing Office:\n\nOffice of Medical Device and Radiological Health Division 1 – East\n\nUnited States\n\nWARNING LETTER\n\nCMS # 618209\n\nOctober 20, 2021\n\nDear Mr. Moon:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at CellEra LLC, located at 1045 Reed Dr, Ste C, Monroe, OH 45050, from June 16 through July 8, 2021. During the inspection, FDA investigators determined that your firm is a specification developer and own label distributor of various sterile wound dressings with drug. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response, dated July 30, 2021 from Ken Heyl, Chief Product Officer, concerning our investigators’ observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued on July 8, 2021. We address the response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for implementing corrective and preventive actions and the failure to document corrective and preventive activities, as required by 21 CFR § 820.100.\n\nSpecifically, your firm does not have a written corrective and preventive action procedure and has failed to document your firm’s corrective actions.\n\nFor example, your firm made changes to your Instructions for Use (IFUs) of your sterile Vitále Silver Calcium Alginate wound dressing as a correction to the findings in the previous inspection ending 05\u002F31\u002F2019. However, your firm failed to implement this change and IFUs reviewed during the current inspection still include the following, which are claims not cleared in (b)(4):\n\n• The term “antimicrobial” was not changed to “antibacterial”\n\n• The statement “The silver-impregnated calcium alginate fibers, when in contact with wound exudate or blood, form a gel which creates a moist wound healing environment. The silver has an antimicrobial effect within the dressing upon various types of microorganisms including Staphylococcus Aureus and Escherichia Coli”.\n\n• The description of “Superficial or Deep” for wound-type.\n\n• The instruction “cleanse the wound with Vitále Cleanser Spray or physiological saline solution.”\n\nNone of your firm’s corrective action activities, including a report of corrective and removal (Z-2085-2019 \u002F RES# 83281) that was reported to the Agency, were documented.\n\nThis is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\n\nWe reviewed your firm’s response and conclude it is not adequate. Your response did not address the creation of a procedure for CAPA activities or your plan to document corrective and preventive actions.\n\nFurther, you provided an updated IFU for the Vitále Silver Calcium Alginate Dressings via email on July 30, 2021. However, you have not provided objective evidence that this new IFU has been approved, the date when the IFU will be included with Vitále Silver Calcium Alginate Dressings, your plan to address the devices currently on the market or ready for distribution that contain an IFU with language beyond what was originally cleared by the Agency under (b)(4). Further, your response did not address initiating a CAPA(s) for the above IFU changes.\n\n2. Failure to establish and maintain procedures to control the design of the device, as required by 21 CFR § 820.30.\n\nSpecifically, your firm has failed to establish design controls that include adequate procedures for design inputs, design outputs, design verifications, design validations, design reviews, design transfers, design changes and the establishment of a design history file.\n\nThis is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\n\nWe reviewed your firm’s response and conclude it is not adequate. You do not address the establishment of procedures to control the design of devices developed by your firm. In your response, please provide your firm’s plan to address the lack of design control procedures and establishment of a design history file.\n\n3. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR § 820.30(i).\n\nSpecifically, your firm indicated to our investigator that an estimated (b)(4) design changes have been made by your firm in the past (b)(4). Some of these design changes include changes to the IFUs for the Vitále Silver Calcium Alginate Dressings beyond the language cleared under (b)(4), the storage requirements for the Vitále Silver Calcium Alginate Dressings from \"Keep from Heat\" “below 77°F” to “41°F \u002F 5°C – 104°F \u002F 40°C”, a change to the sterilization method from (b)(4) to (b)(4), and a change to the shelf life of the Vitále Silver Calcium Alginate Ropes & Dressings from 2 years to 3 years. These design changes have been made without documentation to include validation, verification, review, and approval prior to implementation.\n\nThis is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\n\nWe have reviewed your firm’s response and conclude it is not adequate. Your response indicated that you have drafted a form to use to make changes in products. Your response is not adequate because the “Product Change Request\u002FApproval” form does not include the requirement or allow for documentation of validation, verification (where appropriate), or review of the design change prior to approval. Additionally, you did not provide a retrospective review of design changes your firm has conducted to ensure design change requirements have been met.\n\n4. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements as required by 21 CFR § 820.50.\n\nSpecifically, your firm failed to develop purchasing control procedures and has not established and maintained the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants.\n\nFor example, your firm utilizes (b)(4) contract manufacturers to manufacture the products distributed by your firm. There is no agreement(s) in place that the contract manufacturers agree to notify your firm of changes in the product so your firm can determine whether the changes may affect the quality of a finished device. The storage requirements, sterilization method, and shelf life were changed by the contract manufacturer of your Vitále Silver Calcium Alginate Ropes & Dressings without your firm’s knowledge or approval.\n\nThis is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\n\nWe have reviewed your firm’s response and conclude it is not adequate. Your response indicated that a procedure would be provided by September 8, 2021. To date, a procedure has not been received. Further, your response does not mention how your firm intends to define the type and extent of control to be exercised over contract manufacturers of your products from making changes or if you intend to create an agreement to be notified of changes in products.\n\n5. Failure to establish and maintain procedures for acceptance of incoming product. Incoming product shall be inspected, tested, or otherwise verified as conforming to specified requirements as required by 21 CFR § 820.80(b).\n\nSpecifically, your firm failed to develop procedures for acceptance of incoming product nor does your firm perform any activities related to the acceptance of incoming product other than a visual inspection for noticeable damage to the shipping boxes and device cartons. For example, you stated that sterility certificates received from your contract manufacturers are simply filed and not reviewed.\n\nThis is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\n\nWe have reviewed your firm’s response and conclude it is not adequate. Your response indicated that a procedure would be provided by September 8, 2021. To date, a procedure has not been received.\n\n6. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR § 820.198.\n\nSpecifically, your firm failed to developed procedures for the receipt, review, and evaluation of complaints. For example, your firm receives oral complaints, but no record is made. Complaints received via your firm’s website are maintained in email format without any indication of evaluation by your firm.\n\nThis is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\n\nWe have reviewed your firm’s response and conclude it is not adequate. Your response indicated that your plan to have a formally designated unit to handle complaints and a procedure to follow. This response also indicated that no procedure finish date has been established. To date, a procedure or anticipated date of completion have not been received.\n\n7. Failure to establish and maintain procedures to control all documents as required by 21 CFR § 820.40.\n\nWe have reviewed your firm’s response and conclude it is not adequate. Your response did not address the corrective actions you plan to take. It is unclear if your firm plans to create a document control procedure.\n\n8. Failure to establish and maintain procedures to adequately control environmental conditions, where environmental conditions could reasonably be expected to have an adverse effect on product quality. Environmental control system(s) shall be periodically inspected to verify that the system, including necessary equipment, is adequate and functioning properly. These activities shall be documented and reviewed as required by 21 CFR § 820.70(c).\n\nSpecifically, your firm’s Vitále Silver Calcium Alginate Dressings and Ropes, which are sterile medical devices, have specific temperature storage requirements. Your firm has not developed procedures to adequately control the environmental conditions needed to maintain the environmental requirements, to including storage temperatures, for your devices.\n\nThis is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\n\nWe have reviewed your firm’s response and conclude it is not adequate. Your response indicated that you plan to draft a procedure with a deadline of January 31, 2022. In your response, please provide an explanation why this procedure will take until January 31, 2022 to be established. Additionally, please explain how your firm intends to verify that the (b)(4) temperature and humidity sensors currently in use at your firm are adequate and functioning properly.\n\nOur inspection also revealed that your Vitále Silver Calcium Alginate Dressings and Ropes are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation includes, but is not limited to:\n\n9. Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nSpecifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\n\nWe have reviewed your firm’s response and conclude it is not adequate. In the response, your firm noted you plan to develop these procedures but have not established a date to develop the procedure.\n\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned\n\ncorrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nIf you have questions regarding any issues in this letter, please contact Compliance Officer, Sean Moynihan at 410-779-5134 or at sean.moynihan@fda.hhs.gov. Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nArduino Frankovic\n\nActing Program Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 1 – East\n\nCc:\n\nKen Heyl\n\nChief Product Officer\n\n2044 Grove Park Way\n\nBirmingham, AL 35242","CellEra LLC","cellera-llc-618209-10202021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcellera-llc-618209-10202021","2026-10-26T08:08:12.54362+00:00","Warning Letter","Closed Out","2021-11-02","618209","Medical Devices","2022-07-25","Richard E. Moon","2026-08-20T02:28:11.249+00:00","United Parcel Service","2021-10-20",{"id":34,"raw":35,"subject":41,"body_html":42,"body_text":43,"firm_name":44,"letter_id":45,"created_at":46,"fei_number":20,"letter_url":47,"updated_at":48,"action_type":23,"case_status":49,"posted_date":50,"marcs_cms_no":51,"product_type":52,"closeout_date":20,"issuing_office":39,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":20,"reference_number":56,"action_taken_date":57,"medical_device_id":20,"response_letter_date":20},581,[36,37,38,39,40,13,13,13],"\u003Ctime datetime=\"2025-09-23T04:00:00Z\">09\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-12T04:00:00Z\">09\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcellebration-llc-713252-09122025\">Cellebration LLC \u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-713252\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>George Kaltner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer and President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cellebration LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>(b)(6)\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Juan\u003C\u002Fspan> \u003Cspan>00909\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Puerto Rico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:george@cellebration.com\"> george@cellebration.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 12, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 25-713252\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Kaltner:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) reviewed your company’s website, https:\u002F\u002Fwww.cellebration.com\u002Fconditions (last visited September 2025), through which your company offers cellular products derived from cord blood for use in the treatment or prevention of various diseases or conditions, such as autism, cerebral palsy, chronic pain, colitis, Crohn’s disease, degenerative disease, gout, liver cirrhosis, multiple sclerosis, neurological disorders, Parkinson’s disease, spine and disc conditions, sports injuries, and arthritis. As a result, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>It is a prohibited act under section 301(e) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 331(e), to refuse to permit access to or copying of any record as required by section 704(a) of the FD&amp;C Act, 21 U.S.C. § 374(a).\u003C\u002Fp>\u003Cp>Under section 704(a)(4) of the FD&amp;C Act, 21 U.S.C. § 374(a)(4), you are required to provide within a reasonable timeframe, within reasonable limits, and in a reasonable manner, requested records or information that FDA may inspect under section 704. However, your firm failed to comply with this requirement.\u003C\u002Fp>\u003Cp>Specifically, on October 18, 2024, FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the FD&amp;C Act to the above address. On November 5, 2024, you requested a 30-day extension to the submission deadline. You noted the additional time would allow your firm to “work closely with legal counsel to meet all standards and respond comprehensively.” On November 13, 2024, FDA approved your extension request. On January 3, 2025, your firm requested a second 30-day extension due to the holidays and an unexpected illness. FDA approved this request on January 10, 2025. As you failed to answer our initial request for records, we sent a second request via e-mail on April 23, 2025. You indicated on April 28, 2025, that you had sent your response weeks earlier; however, our records reflect that no such response was received. On May 19, 2025, FDA requested that you resend the response referenced in your email. In response, you stated that you were unclear about what we were seeking. On May 21 and May 28, 2025, we sent additional follow-up emails again asking you to provide the requested records.\u003C\u002Fp>\u003Cp>FDA has not received a response to its request to date even though FDA’s request and follow-up communications sufficiently and clearly described the records sought. Your refusal to permit access to or copying of any record required by section 704(a), 21 U.S.C. § 374(a), violates section 301(e) of the FD&amp;C Act, 21 U.S.C. § 331(e).\u003C\u002Fp>\u003Cp>In response to this letter, we again ask you to provide the information and records requested by FDA pertaining to Cellebration, located at \u003Cstrong>(b)(6)\u003C\u002Fstrong> San Juan, PR, 00909, and your cellular products derived from cord blood.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address this matter. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action being initiated by FDA without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter. If you cannot address this matter within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality&nbsp;&nbsp;\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>Cc:&nbsp;\u003C\u002Fp>\u003Cp>George Kaltner\u003Cbr>Cellebration Regeneration Limited Liability Company\u003Cbr>15 Ave. Munoz Rivera, Suite 103\u003Cbr>Paseo Caribe, San Juan, PR 00901\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-713252\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nGeorge Kaltner\n\nRecipient Title\n\nChief Executive Officer and President\n\nCellebration LLC\n\n(b)(6)\n\nSan Juan 00909\n\nPuerto Rico\n\ngeorge@cellebration.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nSeptember 12, 2025\nCBER 25-713252\nDear Mr. Kaltner:\nThe United States Food and Drug Administration (FDA) reviewed your company’s website, https:\u002F\u002Fwww.cellebration.com\u002Fconditions (last visited September 2025), through which your company offers cellular products derived from cord blood for use in the treatment or prevention of various diseases or conditions, such as autism, cerebral palsy, chronic pain, colitis, Crohn’s disease, degenerative disease, gout, liver cirrhosis, multiple sclerosis, neurological disorders, Parkinson’s disease, spine and disc conditions, sports injuries, and arthritis. As a result, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nIt is a prohibited act under section 301(e) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 331(e), to refuse to permit access to or copying of any record as required by section 704(a) of the FD&C Act, 21 U.S.C. § 374(a).\nUnder section 704(a)(4) of the FD&C Act, 21 U.S.C. § 374(a)(4), you are required to provide within a reasonable timeframe, within reasonable limits, and in a reasonable manner, requested records or information that FDA may inspect under section 704. However, your firm failed to comply with this requirement.\nSpecifically, on October 18, 2024, FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the FD&C Act to the above address. On November 5, 2024, you requested a 30-day extension to the submission deadline. You noted the additional time would allow your firm to “work closely with legal counsel to meet all standards and respond comprehensively.” On November 13, 2024, FDA approved your extension request. On January 3, 2025, your firm requested a second 30-day extension due to the holidays and an unexpected illness. FDA approved this request on January 10, 2025. As you failed to answer our initial request for records, we sent a second request via e-mail on April 23, 2025. You indicated on April 28, 2025, that you had sent your response weeks earlier; however, our records reflect that no such response was received. On May 19, 2025, FDA requested that you resend the response referenced in your email. In response, you stated that you were unclear about what we were seeking. On May 21 and May 28, 2025, we sent additional follow-up emails again asking you to provide the requested records.\nFDA has not received a response to its request to date even though FDA’s request and follow-up communications sufficiently and clearly described the records sought. Your refusal to permit access to or copying of any record required by section 704(a), 21 U.S.C. § 374(a), violates section 301(e) of the FD&C Act, 21 U.S.C. § 331(e).\nIn response to this letter, we again ask you to provide the information and records requested by FDA pertaining to Cellebration, located at (b)(6) San Juan, PR, 00909, and your cellular products derived from cord blood.\nYour firm should take prompt action to address this matter. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action being initiated by FDA without further notice, including, without limitation, seizure and\u002For injunction.\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter. If you cannot address this matter within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response and any questions regarding this letter to CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\nCc:\nGeorge Kaltner\nCellebration Regeneration Limited Liability Company\n15 Ave. Munoz Rivera, Suite 103\nPaseo Caribe, San Juan, PR 00901","Cellebration LLC","cellebration-llc-713252-09122025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcellebration-llc-713252-09122025","2026-10-26T08:08:12.504022+00:00","Issued","2025-09-23","713252","Biologics","George Kaltner","2026-08-19T16:17:34.124+00:00","VIA UPS and Electronic Mail","CBER 25-713252","2025-09-12",{"id":59,"raw":60,"subject":66,"body_html":67,"body_text":68,"firm_name":69,"letter_id":70,"created_at":71,"fei_number":20,"letter_url":72,"updated_at":73,"action_type":23,"case_status":49,"posted_date":74,"marcs_cms_no":75,"product_type":76,"closeout_date":20,"issuing_office":77,"recipient_name":78,"body_fetched_at":79,"delivery_method":80,"recipient_title":20,"reference_number":20,"action_taken_date":81,"medical_device_id":20,"response_letter_date":20},1442,[61,62,63,64,65,13,13,13],"\u003Ctime datetime=\"2024-05-28T13:20:00Z\">05\u002F28\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-05T04:00:00Z\">04\u002F05\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsafari-stem-cell-llc-661023-04052024\">Safari Stem Cell, LLC\u003C\u002Fa>","Division of Biological Products Operations II ","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug\u003Cbr \u002F>\r\n","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Steven D. Garner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Safari Stem Cell, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2402 Marina Bay Drive, Unit E\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>League City\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77573\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:docgarner@safarivet.com\"> docgarner@safarivet.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Biological Products Operations II \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 5, 2024\u003C\u002Fp>\n\n\u003Cp>24-661023\u003Cbr>\n\u003Cbr>\nDear Dr. Garner,\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm, Safari Stem Cell, LLC (hereafter “Safari”), located at 2402 Marina Bay Drive, Unit E, League City, TX 77573, from May 1, 2023, through May 4, 2023, and found that your firm recovers, processes, and distributes cell- and tissue-based products, including platelet-rich plasma, conditioned media, and stem cells derived from various tissues from canine and feline donors. Your products are intended to treat a variety of diseases or conditions. Examples of routes of administration of your products include, but are not limited to, intravenous, intra-articular, and intrathecal. Your products are used individually or in combination (e.g., adipose-derived stem cells with platelet-rich plasma) and are for autologous, allogeneic, or xenogeneic uses. Statements on your website at the internet address www.stemcellsafari.com, your social media sites https:\u002F\u002Fwww.facebook.com\u002FStemCellSafari\u002F, https:\u002F\u002Fvimeo.com\u002Fsafarivet, and https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCp3IvewLTrwVZNjigZF-d1Q, as well as records gathered during the inspection reflect that your products are intended to treat a variety of diseases and conditions, including, but not limited to, intervertebral disc disease (IVDD), chronic kidney disease (CKD), immune mediated hemolytic anemia (IMHA), diabetes mellitus type II, inflammatory bowel disease (IBD), keratoconjunctivitis, inflammatory disorders such as acute liver failure, and degenerative diseases such as arthritis and hip dysplasia.\u003C\u002Fp>\n\n\u003Cp>We have determined that you are marketing unapproved new animal drugs. The cell- and tissue-based products that Safari markets are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals, which makes them drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. § 321(g)(1)(B)]. Further, as discussed below, your products are unapproved new animal drugs and your marketing of them violates the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your correspondence dated May 12, 2023, in which you stated that your firm would cease operations. However, your website indicates that your firm is still manufacturing and distributing your stem cell products. The webpage entitled “How Can I Get Stem Cells For My Pet As Soon As Possible?” (found at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fimmunological-disorders\u002Fhow-can-i-get-stem-cells-for-my-pet-as-soon-as-possible\u002F) provides a phone number and a field for prospective customers to submit contact information and information and medical records about their pet so that they can consult with your firm about your stem cell treatments. The webpage also explains how the treatments can be paid for, shipped, and administered after the consultation.\u003C\u002Fp>\n\n\u003Cp>Statements on your website that show these intended uses of your products include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Found at https:\u002F\u002Fstemcellsafari.com\u002Fservices\u002Fstem-cell-therapy\u002Fconditions-treated-with-stem-cells\u002F :\u003C\u002Fp>\n\n\u003Cp>&nbsp; o “Conditions treated with stem cells\u003Cbr>\n Arthritis\u003Cbr>\n Orthopedic Injuries\u003Cbr>\n Disc Disease\u002FSpinal Cord Injury\u003Cbr>\n Allergic Skin Disease\u003Cbr>\n Kidney Disease \u002F Incontinence\u003Cbr>\n Dry Eye”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o “Stem Cells For Arthritis\u003Cbr>\n Stem Cells are injected directly into the joint space when treating arthritis. Studies have shown that these cells have the ability to regrow cartilage identical to the cartilage that may have been damaged in the arthritis”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o “Intervertebral Disc Disease \u002F Spinal Cord Injury\u003Cbr>\n Stem Cell Therapy for Disc disease and Spinal Cord Injury can be effective if injected directly into the disc”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o “Kidney Disease \u002F Incontinence\u003Cbr>\n Stem cells have shown to regenerate kidney tissue, improve kidney function and reduce metabolite build up.”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o “Dry Eye” Keratoconjunctivitis Sicca\u003Cbr>\n This disease is managed by administration of artificial tears and other medications. While it can be managed, it is never cured with medications. Implanted stem cells are well tolerated and were effective reducing clinical signs of KCS in animals with STT values of 0mm – no tear production at all with a sustained effect.”\u003C\u002Fp>\n\n\u003Cp>Found at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fimmunological-disorders\u002Fkeratoconjunctivitis-sicca\u002F :\u003C\u002Fp>\n\n\u003Cp>&nbsp; o “Keratoconjunctivitis Sicca In Dogs . . .\u003Cbr>\n Stem cells halt the attack on the tear glands by “resetting” the immune system. This means that your dog can be treated once with stem cell injections into his tear glands and third eyelid, and be resolved of the issue for life.”\u003C\u002Fp>\n\n\u003Cp>Found at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Finflammatory-disorders\u002F :\u003Cbr>\n&nbsp; o “Stem cells helps the body heal itself by restarting the healing process, rejuvenating damaged tissue and reducing inflammation.”\u003C\u002Fp>\n\n\u003Cp>Found at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fimmunological-disorders\u002F :\u003Cbr>\n&nbsp; o “Immunological Disorders In Pets . . .\u003Cbr>\n stem cells can “reset” your pet’s immune system and, in most cases, they will resolve their issue for life.”\u003C\u002Fp>\n\n\u003Cp>Found at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fdegenerative-disorders\u002F :\u003Cbr>\n&nbsp; o “Degenerative Diseases In Pets . . .\u003Cbr>\n Stem cells contain growth factors at levels over 1000 times the normal amount. These growth factors can help stop these degenerative diseases in dogs and reverse them in some cases. Regeneration is the process of reversal of degeneration. Mesenchymal Stem Cells (MSC), Platelet Rich Plasma (PRP), Platelet Rich Plasma Lysate (PRP-L), Autologous Conditioned Serum (ACS) and Conditioned Media (CM) are all regenerative products that can cause regeneration of these tissues.”\u003C\u002Fp>\n\n\u003Cp>Found at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fdegenerative-disorders\u002Fintervertebral-disc-disease\u002F :\u003Cbr>\n&nbsp; o “Intervertebral Disc Disease (IVDD) In Dogs . . .\u003Cbr>\n Stem Cell Treatment For IVDD in Dogs\u003Cbr>\n&nbsp; &nbsp; o Treating the intervertebral disc disease in dogs with stem cells into the bad discs and\u002For the spinal canal can prevent disc herniation, as well as treat the existing disease. Stem cells regenerate the cartilage that the discs are made of and draw moisture back inside the disc. The discs become like new, and the owner doesn’t have to watch the dog carefully for signs of the disease returning. Your pet can be treated with one or two stem cell injections, restoring normal function. Note: Safari requires a diagnostic MRI, unless you can present one that is recent and acceptable.”\u003C\u002Fp>\n\n\u003Cp>Found at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fdegenerative-disorders\u002Fchronic-kidney-disease\u002F :\u003Cbr>\n&nbsp; o “Chronic Kidney Disease In Dogs And Cats . . .\u003Cbr>\n Stem cells can restore some of the kidney function that has been lost. Depending on the severity of the condition and when the treatment is given, the kidney values may return to normal or close to normal. Treatment may be injections directly into the kidney or IV injections.”\u003Cbr>\n\u003Cbr>\nFound at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fimmunological-disorders\u002Fdiabetes-mellitus-type-ii\u002F :\u003Cbr>\n&nbsp; o “Diabetes Mellitus Type II . . .\u003Cbr>\n Stem cells “reset” the pet’s immune system. By injecting stem cells, the pet will live longer, healthier life because their hormonal system will not be on the potential roller coaster ride that comes with the artificial regulation of insulin levels. Your pet can be treated with one or two IV injections of stems cells that can restore the body’s ability to regulate glucose levels. Therefore, your pet will no longer need daily insulin injections!”\u003C\u002Fp>\n\n\u003Cp>Found at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fimmunological-disorders\u002Finflammatory-bowel-disease\u002F :\u003Cbr>\n&nbsp; o “Inflammatory Bowel Disease (IBD) in Dogs and Cats . . .\u003Cbr>\n Stem cells halt the attack on gastrointestinal system by \"resetting” the immune system. With IBD in cats &amp; dogs, the immune system wants to attack the inflammation, but the stem cells sort of put themselves in front of the gastrointestinal walls so that they are attacked, and not the gastrointestinal walls. Meanwhile, the inflammation has a chance to subside, the attack stops, and things return to normal. This means that your dog can be treated intravenously with stem cells and be resolved of the issue, rather than just treating the symptoms with medication for Inflammatory Bowel Disease (IBD) in Dogs.”\u003C\u002Fp>\n\n\u003Cp>Found at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Finflammatory-disorders\u002Facute-liver-failure\u002F :.\u003Cbr>\n&nbsp; o “Acute Liver Failure In Dogs . . .\u003Cbr>\n Mesenchymal stem cell (MSC)-based therapy has emerged as a promising strategy for treating liver diseases in dogs via tissue repair and immune regulation.”\u003C\u002Fp>\n\n\u003Cp>From your social media website https:\u002F\u002Fwww.facebook.com\u002FStemCellSafari\u002F: Webpage titled – “Stem Cell Safari | League City TX | Facebook”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; o On your August 18, 2022 post: “This gentle giant got his second round of stem cells today for inflammatory bowel disease. Go \u003Cstrong>(b)(6),&nbsp;(b)(7)(C)\u003C\u002Fstrong>!”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o On your August 11, 2022 post: “\u003Cstrong>(b)(6),&nbsp;(b)(7)(C)\u003C\u002Fstrong> the Standard Poodle came all the way from Illinois to get stem cell injections into his kidneys along with intravenous stem cells to help with his chronic kidney disease.\u003C\u002Fp>\n\n\u003Cp>Stem cells reduce inflammation associated with kidney disease and are angiogenic, meaning they are able to grow new blood vessels to help the kidneys. \u003Cstrong>(b)(6),&nbsp;(b)(7)(C)\u003C\u002Fstrong> will get a second round of cells in 3-4 weeks, at which time we expect his BUN &amp; creatinine levels to have improved.”\u003C\u002Fp>\n\n\u003Cp>From your social media website https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCp3IvewLTrwVZNjigZF-d1Q , Webpage titled Safari Veterinary Care Centers, additional claims observed, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>&nbsp; o In your “Best Regenerative Stem Cell Therapy Hospital for Dogs in League City Texas,” video dated October 21, 2021 at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=Qxq71qI61_k, (at the 0:16 timestamp) the video displays: “Regenerative Stem Cell Therapy. For pets suffering with chronic allergies, arthritis, or orthopedic injury, we now offer in-house, adult stem cell therapy to promote joint relief and tissue regeneration...”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o In your “Treatment of Intervertebral Disc Disease and Stem Cell Therapy for Dogs In League City, TX” video dated Aug 12, 2021 at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=OF5WYOyGVVU, (at the 0:44 timestamp) the video displays: “Safarivet provides regenerative medicine and stem cell therapy for Dogs in League City, TX. Regenerative medicine strives to use the body’s own healing mechanisms to rebuild damaged or missing tissue.”\u003C\u002Fp>\n\n\u003Cp>From your social media website https:\u002F\u002Fvimeo.com\u002Fsafarivet, additional claims observed, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>&nbsp; o In “spinal cord injury stem cell therapy” video dated September 18, 2018, at https:\u002F\u002Fvimeo.com\u002F329751292, (at 0:45 – 1:22 timestamp) the video displays: “Treating Intervertebral Disc Disease in Dogs Using Stem Cells . . . If your pet cannot walk today but could walk yesterday then, your pet has Spinal Cord Injury Which could be treated with Stem Cells to make your pet Walk Again . . . ”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o In “Stem Cells for Disc Disease,” video dated March 20, 2019 at https:\u002F\u002Fvimeo.com\u002F325528141, (at 1:20 – 1:51 timestamp) the video displays: “Stem Cells . . . Decrease Spinal Cord Swelling . . . . Decrease Inflammation . . . Decrease Spinal Scar to Improve Healing . . . Decrease Pain . . . Decrease Neuron Death . . . Stem cells . . . Increase Blood Flow . . . Increase Myelin Life . . . Increase Live Neurons . . . Increase Surgery Success . . . Increase Return to Function . . . Stem Cells . . . SAFE . . . NATURAL . . . EFFECTIVE . . . AFFORDABLE . . .” and (at 2:40 – 2:48 timestamp), “IVDD is a Serious Disease Paralyzing Pets Make Your Decision Now. Choose Stem Cells.”\u003C\u002Fp>\n\n\u003Cp>Because Safari products are intended to diagnose, cure, prevent, mitigate or treat diseases in animals, they are drugs within the meaning of section 201(g)(1)(B) of the FD&amp;C Act, [21 U.S.C. § 321(g)(1)(B)]. Moreover, your products are new animal drugs, as defined by section 201(v) of the FD&amp;C Act, [21 U.S.C. § 321(v)], because they are not generally recognized among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. The products are not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. Therefore, the products are unsafe within the meaning of section 512(a) [21 U.S.C. § 360b(a)] of the FD&amp;C Act and adulterated under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. § 351(a)(5)].\u003C\u002Fp>\n\n\u003Cp>During the inspection, FDA Investigators documented significant deviations from the Current Good Manufacturing Practice (CGMP) regulations for Finished Pharmaceuticals, Title 21, Code of Federal Regulations, Part 211. These violations cause your animal drug products to be adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 351(a)(2)(B)] in that the methods used in, or the facilities or controls used for, their manufacture, processing, packing, or holding do not conform to, or are not operated or administered in conformity with current good manufacturing practice. At the conclusion of the inspection, the FDA investigators issued a Form FDA 483, Inspectional Observations, which described significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the inspection. Specific deviations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity that they purport or are represented to possess [21 CFR 211.100(a)]. You have not established written procedures that describe the manufacture of stem cells from umbilical cord and bone marrow.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and follow written procedures that describe the in-process controls, and tests, or examinations to be conducted on appropriate samples of in-process materials of each batch [21 CFR 211.110(a)]. You are required to establish such control procedures to monitor the output and to validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product. Our investigation found that you do not validate the manufacturing processes for isolating the stem cells derived from culture expanded adipose tissue, umbilical cord, and bone marrow.\u003C\u002Fp>\n\n\u003Cp>3. Failure to perform appropriate laboratory testing, as necessary, of each batch of drug product required to be free of objectionable microorganisms [21 CFR 211.165(b)]. Specifically, you failed to perform appropriate laboratory testing, including sterility testing, on at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of the stem cell products derived from adipose tissue, umbilical cord, and bone marrow which are administered intravenously or intrathecally.\u003C\u002Fp>\n\n\u003Cp>4. Failure to have a system for monitoring environmental conditions in an aseptic processing area [21 CFR 211.42(c)(10)(iv)]. Specifically, your firm has not established a system for environmental monitoring in the aseptic processing area where stem cell products derived from adipose tissue, umbilical cord, and bone marrow are manufactured.\u003C\u002Fp>\n\n\u003Cp>5. Failure to make, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to the final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. [21 CFR § 211.165(a)]. Specifically, there are no written specifications or procedures that define all analytical or documentation criteria for release for distribution of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of stem cells derived from adipose tissue, umbilical cord, and bone marrow.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish and follow written procedures for cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing, or holding of a drug product [21 CFR 211.67(b)]. You do not have written cleaning procedures for the manufacturing of your culture expanded allogeneic adipose-derived animal cell product. Furthermore, your firm does not keep cleaning records, as required by 21 CFR 211.67(c).\u003C\u002Fp>\n\n\u003Cp>7. Failure to establish and follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)] (see also 21 CFR 211.180(e)(2)). Our investigation found that you do not have written procedures for handling or investigating complaints.\u003C\u002Fp>\n\n\u003Cp>8. Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)]. Specifically, your batch production records do not include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding your products or the person(s) performing each of those steps for stem cell products derived from adipose tissue, umbilical cord, and bone marrow.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food &amp; Drug Administration, Office of Biological Product Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 248-8146 x 104 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nSteven D. Garner\n\nRecipient Title\n\nOwner\n\nSafari Stem Cell, LLC\n\n2402 Marina Bay Drive, Unit E\n\nLeague City, TX 77573\n\nUnited States\n\ndocgarner@safarivet.com\n\nIssuing Office:\n\nDivision of Biological Products Operations II\n\nUnited States\n\nWARNING LETTER\n\nApril 5, 2024\n\n24-661023\n\nDear Dr. Garner,\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm, Safari Stem Cell, LLC (hereafter “Safari”), located at 2402 Marina Bay Drive, Unit E, League City, TX 77573, from May 1, 2023, through May 4, 2023, and found that your firm recovers, processes, and distributes cell- and tissue-based products, including platelet-rich plasma, conditioned media, and stem cells derived from various tissues from canine and feline donors. Your products are intended to treat a variety of diseases or conditions. Examples of routes of administration of your products include, but are not limited to, intravenous, intra-articular, and intrathecal. Your products are used individually or in combination (e.g., adipose-derived stem cells with platelet-rich plasma) and are for autologous, allogeneic, or xenogeneic uses. Statements on your website at the internet address www.stemcellsafari.com, your social media sites https:\u002F\u002Fwww.facebook.com\u002FStemCellSafari\u002F, https:\u002F\u002Fvimeo.com\u002Fsafarivet, and https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCp3IvewLTrwVZNjigZF-d1Q, as well as records gathered during the inspection reflect that your products are intended to treat a variety of diseases and conditions, including, but not limited to, intervertebral disc disease (IVDD), chronic kidney disease (CKD), immune mediated hemolytic anemia (IMHA), diabetes mellitus type II, inflammatory bowel disease (IBD), keratoconjunctivitis, inflammatory disorders such as acute liver failure, and degenerative diseases such as arthritis and hip dysplasia.\n\nWe have determined that you are marketing unapproved new animal drugs. The cell- and tissue-based products that Safari markets are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals, which makes them drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. § 321(g)(1)(B)]. Further, as discussed below, your products are unapproved new animal drugs and your marketing of them violates the FD&C Act.\n\nWe acknowledge receipt of your correspondence dated May 12, 2023, in which you stated that your firm would cease operations. However, your website indicates that your firm is still manufacturing and distributing your stem cell products. The webpage entitled “How Can I Get Stem Cells For My Pet As Soon As Possible?” (found at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fimmunological-disorders\u002Fhow-can-i-get-stem-cells-for-my-pet-as-soon-as-possible\u002F) provides a phone number and a field for prospective customers to submit contact information and information and medical records about their pet so that they can consult with your firm about your stem cell treatments. The webpage also explains how the treatments can be paid for, shipped, and administered after the consultation.\n\nStatements on your website that show these intended uses of your products include, but are not limited to, the following:\n\nFound at https:\u002F\u002Fstemcellsafari.com\u002Fservices\u002Fstem-cell-therapy\u002Fconditions-treated-with-stem-cells\u002F :\n\no “Conditions treated with stem cells\n\n Arthritis\n\n Orthopedic Injuries\n\n Disc Disease\u002FSpinal Cord Injury\n\n Allergic Skin Disease\n\n Kidney Disease \u002F Incontinence\n\n Dry Eye”\n\no “Stem Cells For Arthritis\n\n Stem Cells are injected directly into the joint space when treating arthritis. Studies have shown that these cells have the ability to regrow cartilage identical to the cartilage that may have been damaged in the arthritis”\n\no “Intervertebral Disc Disease \u002F Spinal Cord Injury\n\n Stem Cell Therapy for Disc disease and Spinal Cord Injury can be effective if injected directly into the disc”\n\no “Kidney Disease \u002F Incontinence\n\n Stem cells have shown to regenerate kidney tissue, improve kidney function and reduce metabolite build up.”\n\no “Dry Eye” Keratoconjunctivitis Sicca\n\n This disease is managed by administration of artificial tears and other medications. While it can be managed, it is never cured with medications. Implanted stem cells are well tolerated and were effective reducing clinical signs of KCS in animals with STT values of 0mm – no tear production at all with a sustained effect.”\n\nFound at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fimmunological-disorders\u002Fkeratoconjunctivitis-sicca\u002F :\n\no “Keratoconjunctivitis Sicca In Dogs . . .\n\n Stem cells halt the attack on the tear glands by “resetting” the immune system. This means that your dog can be treated once with stem cell injections into his tear glands and third eyelid, and be resolved of the issue for life.”\n\nFound at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Finflammatory-disorders\u002F :\n\no “Stem cells helps the body heal itself by restarting the healing process, rejuvenating damaged tissue and reducing inflammation.”\n\nFound at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fimmunological-disorders\u002F :\n\no “Immunological Disorders In Pets . . .\n\n stem cells can “reset” your pet’s immune system and, in most cases, they will resolve their issue for life.”\n\nFound at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fdegenerative-disorders\u002F :\n\no “Degenerative Diseases In Pets . . .\n\n Stem cells contain growth factors at levels over 1000 times the normal amount. These growth factors can help stop these degenerative diseases in dogs and reverse them in some cases. Regeneration is the process of reversal of degeneration. Mesenchymal Stem Cells (MSC), Platelet Rich Plasma (PRP), Platelet Rich Plasma Lysate (PRP-L), Autologous Conditioned Serum (ACS) and Conditioned Media (CM) are all regenerative products that can cause regeneration of these tissues.”\n\nFound at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fdegenerative-disorders\u002Fintervertebral-disc-disease\u002F :\n\no “Intervertebral Disc Disease (IVDD) In Dogs . . .\n\n Stem Cell Treatment For IVDD in Dogs\n\no Treating the intervertebral disc disease in dogs with stem cells into the bad discs and\u002For the spinal canal can prevent disc herniation, as well as treat the existing disease. Stem cells regenerate the cartilage that the discs are made of and draw moisture back inside the disc. The discs become like new, and the owner doesn’t have to watch the dog carefully for signs of the disease returning. Your pet can be treated with one or two stem cell injections, restoring normal function. Note: Safari requires a diagnostic MRI, unless you can present one that is recent and acceptable.”\n\nFound at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fdegenerative-disorders\u002Fchronic-kidney-disease\u002F :\n\no “Chronic Kidney Disease In Dogs And Cats . . .\n\n Stem cells can restore some of the kidney function that has been lost. Depending on the severity of the condition and when the treatment is given, the kidney values may return to normal or close to normal. Treatment may be injections directly into the kidney or IV injections.”\n\nFound at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fimmunological-disorders\u002Fdiabetes-mellitus-type-ii\u002F :\n\no “Diabetes Mellitus Type II . . .\n\n Stem cells “reset” the pet’s immune system. By injecting stem cells, the pet will live longer, healthier life because their hormonal system will not be on the potential roller coaster ride that comes with the artificial regulation of insulin levels. Your pet can be treated with one or two IV injections of stems cells that can restore the body’s ability to regulate glucose levels. Therefore, your pet will no longer need daily insulin injections!”\n\nFound at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Fimmunological-disorders\u002Finflammatory-bowel-disease\u002F :\n\no “Inflammatory Bowel Disease (IBD) in Dogs and Cats . . .\n\n Stem cells halt the attack on gastrointestinal system by \"resetting” the immune system. With IBD in cats & dogs, the immune system wants to attack the inflammation, but the stem cells sort of put themselves in front of the gastrointestinal walls so that they are attacked, and not the gastrointestinal walls. Meanwhile, the inflammation has a chance to subside, the attack stops, and things return to normal. This means that your dog can be treated intravenously with stem cells and be resolved of the issue, rather than just treating the symptoms with medication for Inflammatory Bowel Disease (IBD) in Dogs.”\n\nFound at https:\u002F\u002Fstemcellsafari.com\u002Fconditions-treated\u002Finflammatory-disorders\u002Facute-liver-failure\u002F :.\n\no “Acute Liver Failure In Dogs . . .\n\n Mesenchymal stem cell (MSC)-based therapy has emerged as a promising strategy for treating liver diseases in dogs via tissue repair and immune regulation.”\n\nFrom your social media website https:\u002F\u002Fwww.facebook.com\u002FStemCellSafari\u002F: Webpage titled – “Stem Cell Safari | League City TX | Facebook”:\n\no On your August 18, 2022 post: “This gentle giant got his second round of stem cells today for inflammatory bowel disease. Go (b)(6), (b)(7)(C)!”\n\no On your August 11, 2022 post: “(b)(6), (b)(7)(C) the Standard Poodle came all the way from Illinois to get stem cell injections into his kidneys along with intravenous stem cells to help with his chronic kidney disease.\n\nStem cells reduce inflammation associated with kidney disease and are angiogenic, meaning they are able to grow new blood vessels to help the kidneys. (b)(6), (b)(7)(C) will get a second round of cells in 3-4 weeks, at which time we expect his BUN & creatinine levels to have improved.”\n\nFrom your social media website https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCp3IvewLTrwVZNjigZF-d1Q , Webpage titled Safari Veterinary Care Centers, additional claims observed, but not limited to, the following:\n\no In your “Best Regenerative Stem Cell Therapy Hospital for Dogs in League City Texas,” video dated October 21, 2021 at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=Qxq71qI61_k, (at the 0:16 timestamp) the video displays: “Regenerative Stem Cell Therapy. For pets suffering with chronic allergies, arthritis, or orthopedic injury, we now offer in-house, adult stem cell therapy to promote joint relief and tissue regeneration...”\n\no In your “Treatment of Intervertebral Disc Disease and Stem Cell Therapy for Dogs In League City, TX” video dated Aug 12, 2021 at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=OF5WYOyGVVU, (at the 0:44 timestamp) the video displays: “Safarivet provides regenerative medicine and stem cell therapy for Dogs in League City, TX. Regenerative medicine strives to use the body’s own healing mechanisms to rebuild damaged or missing tissue.”\n\nFrom your social media website https:\u002F\u002Fvimeo.com\u002Fsafarivet, additional claims observed, but not limited to, the following:\n\no In “spinal cord injury stem cell therapy” video dated September 18, 2018, at https:\u002F\u002Fvimeo.com\u002F329751292, (at 0:45 – 1:22 timestamp) the video displays: “Treating Intervertebral Disc Disease in Dogs Using Stem Cells . . . If your pet cannot walk today but could walk yesterday then, your pet has Spinal Cord Injury Which could be treated with Stem Cells to make your pet Walk Again . . . ”\n\no In “Stem Cells for Disc Disease,” video dated March 20, 2019 at https:\u002F\u002Fvimeo.com\u002F325528141, (at 1:20 – 1:51 timestamp) the video displays: “Stem Cells . . . Decrease Spinal Cord Swelling . . . . Decrease Inflammation . . . Decrease Spinal Scar to Improve Healing . . . Decrease Pain . . . Decrease Neuron Death . . . Stem cells . . . Increase Blood Flow . . . Increase Myelin Life . . . Increase Live Neurons . . . Increase Surgery Success . . . Increase Return to Function . . . Stem Cells . . . SAFE . . . NATURAL . . . EFFECTIVE . . . AFFORDABLE . . .” and (at 2:40 – 2:48 timestamp), “IVDD is a Serious Disease Paralyzing Pets Make Your Decision Now. Choose Stem Cells.”\n\nBecause Safari products are intended to diagnose, cure, prevent, mitigate or treat diseases in animals, they are drugs within the meaning of section 201(g)(1)(B) of the FD&C Act, [21 U.S.C. § 321(g)(1)(B)]. Moreover, your products are new animal drugs, as defined by section 201(v) of the FD&C Act, [21 U.S.C. § 321(v)], because they are not generally recognized among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. The products are not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. Therefore, the products are unsafe within the meaning of section 512(a) [21 U.S.C. § 360b(a)] of the FD&C Act and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)].\n\nDuring the inspection, FDA Investigators documented significant deviations from the Current Good Manufacturing Practice (CGMP) regulations for Finished Pharmaceuticals, Title 21, Code of Federal Regulations, Part 211. These violations cause your animal drug products to be adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug and Cosmetic Act (FD&C Act) [21 U.S.C. § 351(a)(2)(B)] in that the methods used in, or the facilities or controls used for, their manufacture, processing, packing, or holding do not conform to, or are not operated or administered in conformity with current good manufacturing practice. At the conclusion of the inspection, the FDA investigators issued a Form FDA 483, Inspectional Observations, which described significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the inspection. Specific deviations include, but are not limited to, the following:\n\n1. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity that they purport or are represented to possess [21 CFR 211.100(a)]. You have not established written procedures that describe the manufacture of stem cells from umbilical cord and bone marrow.\n\n2. Failure to establish and follow written procedures that describe the in-process controls, and tests, or examinations to be conducted on appropriate samples of in-process materials of each batch [21 CFR 211.110(a)]. You are required to establish such control procedures to monitor the output and to validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product. Our investigation found that you do not validate the manufacturing processes for isolating the stem cells derived from culture expanded adipose tissue, umbilical cord, and bone marrow.\n\n3. Failure to perform appropriate laboratory testing, as necessary, of each batch of drug product required to be free of objectionable microorganisms [21 CFR 211.165(b)]. Specifically, you failed to perform appropriate laboratory testing, including sterility testing, on at least (b)(4) batches of the stem cell products derived from adipose tissue, umbilical cord, and bone marrow which are administered intravenously or intrathecally.\n\n4. Failure to have a system for monitoring environmental conditions in an aseptic processing area [21 CFR 211.42(c)(10)(iv)]. Specifically, your firm has not established a system for environmental monitoring in the aseptic processing area where stem cell products derived from adipose tissue, umbilical cord, and bone marrow are manufactured.\n\n5. Failure to make, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to the final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. [21 CFR § 211.165(a)]. Specifically, there are no written specifications or procedures that define all analytical or documentation criteria for release for distribution of (b)(4) batches of stem cells derived from adipose tissue, umbilical cord, and bone marrow.\n\n6. Failure to establish and follow written procedures for cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing, or holding of a drug product [21 CFR 211.67(b)]. You do not have written cleaning procedures for the manufacturing of your culture expanded allogeneic adipose-derived animal cell product. Furthermore, your firm does not keep cleaning records, as required by 21 CFR 211.67(c).\n\n7. Failure to establish and follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)] (see also 21 CFR 211.180(e)(2)). Our investigation found that you do not have written procedures for handling or investigating complaints.\n\n8. Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)]. Specifically, your batch production records do not include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding your products or the person(s) performing each of those steps for stem cell products derived from adipose tissue, umbilical cord, and bone marrow.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food & Drug Administration, Office of Biological Product Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 248-8146 x 104 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2","Safari Stem Cell, LLC","safari-stem-cell-llc-661023-04052024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsafari-stem-cell-llc-661023-04052024","2026-10-26T08:09:52.542623+00:00","2024-05-28","661023","Drugs","Division of Biological Products Operations II","Steven D. Garner","2026-08-20T00:04:11.506+00:00","VIA UNITED PARCEL SERVICE","2024-04-05",{"id":83,"raw":84,"subject":89,"body_html":90,"body_text":91,"firm_name":92,"letter_id":93,"created_at":94,"fei_number":20,"letter_url":95,"updated_at":96,"action_type":23,"case_status":49,"posted_date":97,"marcs_cms_no":98,"product_type":52,"closeout_date":20,"issuing_office":88,"recipient_name":99,"body_fetched_at":100,"delivery_method":55,"recipient_title":20,"reference_number":101,"action_taken_date":102,"medical_device_id":20,"response_letter_date":20},329,[85,86,87,88,89,13,13,13],"\u003Ctime datetime=\"2026-02-24T05:00:00Z\">02\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-11T05:00:00Z\">02\u002F11\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdynamic-stem-cell-therapy-712579-02112026\">Dynamic Stem Cell Therapy\u003C\u002Fa>","Center for Biologics Evaluation and Research","Unapproved New Drugs\u002FUnlicensed Biological Product Violations","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-712579\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dale Carrison, D.O., FACEP, FACOEP\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Medical Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Dynamic Stem Cell Therapy\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2551 N. Green Valley Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Building C, Suite 305C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Henderson\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89014\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Contact@stemcellpowernow.com\"> Contact@stemcellpowernow.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 11, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 25-712579\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Dr. Carrison:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) reviewed your company’s website at https:\u002F\u002Fstemcellpowernow.com (last visited February 2026), through which your company markets an umbilical cord-derived stem cell product for allogeneic use (hereinafter, “your umbilical-cord derived product”).\u003C\u002Fp>\u003Cp>This letter is to advise you that your misbranding of your umbilical-cord derived product while held for sale after shipment in interstate commerce violates section 301(k) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 331(k).\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, https:\u002F\u002Fstemcellpowernow.com (last visited February 2026), your umbilical-cord derived product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For is intended to affect the structure or function of the body. For example, you make the following claims about stem cells (which you state are used to make your umbilical-cord derived product):\u003C\u002Fp>\u003Cul>\u003Cli>Under a title of Regenerative Medicine for Sports Injuries, “There are a number of different types of sports injuries that can be treated with stem cells, including:\u003Cbr>o Knee injuries such as ligament tears and cartilage damage\u003Cbr>o Shoulder injuries such as rotator cuff tears and bursitis\u003Cbr>o Ankle and foot injuries such as ankle sprains and Achilles tendon ruptures\u003Cbr>o Hip injuries such as hip labral tears and arthritis\u003Cbr>o Muscle strains and tears”\u003C\u002Fli>\u003Cli>Under a title of Anti-Aging Stem Cell Therapy, “Anti-aging isn't the only amazing thing stem cell therapy can do--it has also been shown to improve various conditions resulting from injuries, like knee pain, spinal cord injury, joint pain, cardiovascular disease, and arthritis.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your umbilical-cord derived product is a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your umbilical-cord derived product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Dynamic Stem Cell Therapy does not qualify for any exception in 21 CFR 1271.15, and your umbilical-cord derived product fails to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your umbilical-cord derived product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\u003C\u002Fp>\u003Cp>In addition, your umbilical-cord derived product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your umbilical-cord derived product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your umbilical-cord derived product is intended for use in the treatment of cardiovascular disease or arthritis, for example, which is not a basic function of the human umbilical cord in the donor.\u003C\u002Fp>\u003Cp>Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your umbilical-cord derived product is regulated as a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Your umbilical-cord derived product is a misbranded drug under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. § 352(f)(1). A drug is misbranded under section 502(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. 21 CFR 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act, 21 U.S.C. § 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your umbilical-cord derived product is intended for use in the treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your umbilical-cord derived product safely for its intended purposes. Accordingly, your umbilical-cord derived product fails to bear adequate directions for its intended uses and, therefore, is misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. § 352(f)(1). Misbranding your umbilical-cord derived product while it is held for sale after shipment of the drug or one or more of its components in interstate commerce is prohibited under section 301(k) of the FD&amp;C Act, 21 U.S.C. § 331(k).\u003C\u002Fp>\u003Cp>Your umbilical-cord derived product is not the subject of an approved biologics license application (BLA) under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. If your umbilical-cord derived product was the subject of an approved BLA and labeled consistent with the approval, it would bear adequate directions for its intended uses, and subject to exceptions not applicable here, it could be lawfully introduced or delivered for introduction into interstate commerce.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concern\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition to the violations described above, we offer the following comment:\u003C\u002Fp>\u003Cul>\u003Cli>FDA’s review of your website also found that you market exosomes. As a general matter, exosomes intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body are subject to requirements for drugs, as defined in section 201(g)(1) of the FD&amp;C Act, and biological products under section 351 of the PHS Act, including applicable premarket review and approval requirements. We also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your umbilical-cord derived product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your umbilical-cord derived product is in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Because your umbilical-cord derived product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-712579\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nDale Carrison, D.O., FACEP, FACOEP\n\nRecipient Title\n\nMedical Director\n\nDynamic Stem Cell Therapy\n\n2551 N. Green Valley Parkway\n\nBuilding C, Suite 305C\n\nHenderson, NV 89014\n\nUnited States\n\nContact@stemcellpowernow.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\nFebruary 11, 2026\nCBER 25-712579\nDear Dr. Carrison:\nThe United States Food and Drug Administration (FDA) reviewed your company’s website at https:\u002F\u002Fstemcellpowernow.com (last visited February 2026), through which your company markets an umbilical cord-derived stem cell product for allogeneic use (hereinafter, “your umbilical-cord derived product”).\nThis letter is to advise you that your misbranding of your umbilical-cord derived product while held for sale after shipment in interstate commerce violates section 301(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 331(k).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information and records reviewed by FDA, https:\u002F\u002Fstemcellpowernow.com (last visited February 2026), your umbilical-cord derived product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For is intended to affect the structure or function of the body. For example, you make the following claims about stem cells (which you state are used to make your umbilical-cord derived product):\nUnder a title of Regenerative Medicine for Sports Injuries, “There are a number of different types of sports injuries that can be treated with stem cells, including:\no Knee injuries such as ligament tears and cartilage damage\no Shoulder injuries such as rotator cuff tears and bursitis\no Ankle and foot injuries such as ankle sprains and Achilles tendon ruptures\no Hip injuries such as hip labral tears and arthritis\no Muscle strains and tears”\nUnder a title of Anti-Aging Stem Cell Therapy, “Anti-aging isn't the only amazing thing stem cell therapy can do--it has also been shown to improve various conditions resulting from injuries, like knee pain, spinal cord injury, joint pain, cardiovascular disease, and arthritis.”\nTherefore, your umbilical-cord derived product is a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).\nYour umbilical-cord derived product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Dynamic Stem Cell Therapy does not qualify for any exception in 21 CFR 1271.15, and your umbilical-cord derived product fails to meet all criteria in 21 CFR 1271.10(a).\nFor example, your umbilical-cord derived product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your umbilical-cord derived product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your umbilical-cord derived product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your umbilical-cord derived product is intended for use in the treatment of cardiovascular disease or arthritis, for example, which is not a basic function of the human umbilical cord in the donor.\nTherefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.1 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your umbilical-cord derived product is regulated as a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nYour umbilical-cord derived product is a misbranded drug under section 502(f)(1) of the FD&C Act, 21 U.S.C. § 352(f)(1). A drug is misbranded under section 502(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. 21 CFR 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, 21 U.S.C. § 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour umbilical-cord derived product is intended for use in the treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your umbilical-cord derived product safely for its intended purposes. Accordingly, your umbilical-cord derived product fails to bear adequate directions for its intended uses and, therefore, is misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. § 352(f)(1). Misbranding your umbilical-cord derived product while it is held for sale after shipment of the drug or one or more of its components in interstate commerce is prohibited under section 301(k) of the FD&C Act, 21 U.S.C. § 331(k).\nYour umbilical-cord derived product is not the subject of an approved biologics license application (BLA) under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. If your umbilical-cord derived product was the subject of an approved BLA and labeled consistent with the approval, it would bear adequate directions for its intended uses, and subject to exceptions not applicable here, it could be lawfully introduced or delivered for introduction into interstate commerce.\nAdditional Concern\nIn addition to the violations described above, we offer the following comment:\nFDA’s review of your website also found that you market exosomes. As a general matter, exosomes intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body are subject to requirements for drugs, as defined in section 201(g)(1) of the FD&C Act, and biological products under section 351 of the PHS Act, including applicable premarket review and approval requirements. We also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nConclusion\nThis letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your umbilical-cord derived product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your umbilical-cord derived product is in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n___________________\n1 Because your umbilical-cord derived product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Dynamic Stem Cell Therapy","dynamic-stem-cell-therapy-712579-02112026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdynamic-stem-cell-therapy-712579-02112026","2026-10-26T08:08:28.902666+00:00","2026-02-24","712579","Dale Carrison, D.O., FACEP, FACOEP","2026-08-19T04:56:57.212+00:00","CBER 25-712579","2026-02-11",{"id":104,"raw":105,"subject":41,"body_html":110,"body_text":111,"firm_name":112,"letter_id":113,"created_at":19,"fei_number":20,"letter_url":114,"updated_at":115,"action_type":23,"case_status":49,"posted_date":116,"marcs_cms_no":117,"product_type":52,"closeout_date":20,"issuing_office":109,"recipient_name":118,"body_fetched_at":119,"delivery_method":80,"recipient_title":20,"reference_number":20,"action_taken_date":120,"medical_device_id":20,"response_letter_date":20},3205,[106,107,108,109,40,13,13,13],"\u003Ctime datetime=\"2021-08-17T13:20:00Z\">08\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-10T04:00:00Z\">08\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Futah-cord-bank-llc-dba-utah-cell-bank-614013-08102021\">Utah Cord Bank LLC dba Utah Cell Bank\u003C\u002Fa>","Office of Biological Products Operations - Division 2","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Eliott D. Spencer, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u002FPresident\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Utah Cord Bank LLC dba Utah Cell Bank\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8675 S. Sandy Parkway, Suite 110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sandy\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84070-6418\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations - Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 10, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter #OBPO 21-614013\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Spencer:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firms, Utah Cord Bank LLC (Utah Cord Bank), dba Utah Cell Bank, and FIOR Bioscience LLC (FIOR Bioscience), co-located at 8675 S. Sandy Parkway, Suite 110, Sandy, UT 84070, conducted between February 1 and February 11, 2021, United States Food and Drug Administration (FDA) investigators documented that you manufacture cellular products for allogeneic use, including: human umbilical cord blood, umbilical cord, and amniotic membrane derived cellular products with the brand names StemVive® and StemMaxx™ (also known as Stemii and Stemshot); a human umbilical cord blood derived product with the brand name StemTru™; and a human umbilical cord derived product with the brand name StemCellect™ (collectively, “your products”).\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> FIOR Bioscience distributes your products directly to health care professionals and medical facilities. These products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to and at the time of the inspection, including information on the FIOR Bioscience website, https:\u002F\u002Ffiorbio.com reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264].\u003C\u002Fp>\n\n\u003Cp>HCT\u002FPs that do not meet all the criteria set forth in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Your establishments do not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all the criteria in 21 CFR 1271.10(a). Therefore, your products are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>Specifically, an HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” StemVive® and StemMaxx™ are not intended to perform the same basic function or functions of umbilical cord blood, umbilical cord, or amniotic membrane in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system (for cord blood); serving as a conduit (for umbilical cord); or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, using these products to treat orthopedic conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>In addition, your products fail to meet other criteria set forth in 21 CFR 1271.10(a). For example, StemVive®, StemMaxx™, and StemTru™ fail to meet 21 CFR 1271.10(a)(4). These cellular products, manufactured at least in part from donated umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use. In addition, StemVive®, StemMaxx™, and StemCellect™ fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord and\u002For amniotic membrane related to their utility for reconstruction, repair, or replacement.\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210, 211, and 1271.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, the FDA investigators issued a Form FDA 483 to you listing inspectional observations, which described a number of significant deviations from CGMP and CGTP applicable to your products. The deficiencies include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the aseptic processes used to manufacture over \u003Cstrong>(b)(4) \u003C\u002Fstrong>vials of your StemVive®, StemMaxx™; StemTru™ and StemCellect™ products (i.e., by performing media fill simulations) since your manufacturing operations began. By the nature of their routes of administration, your products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\n\n\u003Cp>b. Your employees use non-sterile personal protective equipment (PPE), for example lab coats, gloves and hair nets, during the manufacture of your products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to have separate or defined areas or such other control systems for your operations as are necessary to prevent contamination or mixups during the course of aseptic processing. [21 CFR 211.42(c)(10)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You allow two or more operators to process product within the same \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Processing by more than one technician in the same \u003Cstrong>(b)(4)\u003C\u002Fstrong> can significantly increase the potential for contamination.\u003C\u002Fp>\n\n\u003Cp>b. Your manufacturing facility is not classified with respect to air quality. The \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used to process your products, and operator gowning areas are located within an unclassified environment.\u003C\u002Fp>\n\n\u003Cp>c. Your firm has not established an adequate system for monitoring environmental conditions in the aseptic processing area where your products are manufactured.\u003C\u002Fp>\n\n\u003Cp>d. Your firm does not conduct personnel monitoring of operators working in the aseptic processing area where your products are manufactured.\u003C\u002Fp>\n\n\u003Cp>e. Your firm does not have a validated cleaning process for the aseptic processing area where your products are manufactured.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not established scientifically sound and appropriate specifications, standards, sampling plans and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>b. You do not collect and test sterility samples that are representative of the lot size. You test \u003Cstrong>(b)(4)\u003C\u002Fstrong> for sterility and rely on the results of \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility test to determine lot release despite the lot size, which may consist of as many as \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to include in laboratory records complete data derived from all tests necessary to assure compliance with established specifications and standards, including a statement of each method used in the testing of the sample that indicates the location of data that establish that the methods used in the testing of the sample meet proper standards of accuracy and reliability as applied to the product tested [21 CFR 211.194(a)(2)].\u003C\u002Fstrong> Specifically, lot release of your products is based on sterility testing; however, your in-house sterility test has not been validated. Accordingly, your laboratory records do not include a statement that indicates the location of data that establish that your sterility testing methods meet proper standards of accuracy and reliability as applied to your products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> Specifically, the manufacturing processes for your products have not been validated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish and follow written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, testing, and approval or rejection of components and drug product containers and closures [21 CFR 211.80(a)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. There are no written procedures describing in sufficient detail the criteria for approval or rejection of incoming human umbilical cord blood or human umbilical cord.\u003C\u002Fp>\n\n\u003Cp>b. There are no written procedures describing in sufficient detail the acceptance criteria for components used in manufacturing, including \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>micron and \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>micron filters, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (glass) bottles, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and drug product containers and closures.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [21 CFR 211.67(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the cleaning process for your \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>b. There are no data or rationale for the cleaning agents used or their rotation for the cleaning of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> where manufacturing is performed.\u003C\u002Fp>\n\n\u003Cp>c. Your firm has not established written procedures for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filter and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> funnel that come into direct contact with your products during processing.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192].\u003C\u002Fstrong> Specifically, from July 2017 to January 2020, you failed to thoroughly investigate 16 sterility failures. The failed lots were discarded; however, there was no further evaluation to identify the contaminating microorganism, determine a root cause or determine if other product lots may have been affected by the failures.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine the appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, you assign a two-to-six year expiration date to your products without supporting data.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Failure to establish and follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Although your firm received multiple complaints regarding your products, there was no supporting documentation to show that you performed an adequate follow-up and\u002For investigation of those complaints. We note that these complaints were categorized as adverse events on your complaint log.\u003C\u002Fp>\n\n\u003Cp>b. Written procedures describing the handling of all written and oral complaints do not include procedures for review of a complaint to determine whether the complaint represents a serious and\u002For unexpected adverse experience.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>11. Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your batch production record does not include documentation of the accomplishment of each significant step in the processing of your products as described in your work instructions. These work instructions include GLP-DOC-0008 entitled “Amniotic Membrane Injectable Product Isolation Processing Work Instruction”; GLP-DOC-0009, Revision 01 entitled “Cord Tissue and Blood Injectable Product Isolation Processing Work Instruction”; and GLP-DOC-010 entitled “Cord Tissue Flowable Product Isolation Processing Work Instruction.”\u003C\u002Fp>\n\n\u003Cp>b. The batch production record does not include documentation of the identity of each batch of component or in-process material used in the processing of your products.\u003C\u002Fp>\n\n\u003Cp>c. The batch production record does not consistently document the results of product sterility testing.\u003C\u002Fp>\n\n\u003Cp>d. The batch production record does not include a statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing (i.e., the quantity of vials produced in each product lot).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>12. Failure to establish, when appropriate, time limits for the completion of each phase of production to assure the quality of the drug product [21 CFR 211.111].\u003C\u002Fstrong> Specifically, your firm stores \u003Cstrong>(b)(4)\u003C\u002Fstrong> product (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ml glass container in a commercial refrigerator in your unclassified lab area for up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to aliquoting the \u003Cstrong>(b)(4)\u003C\u002Fstrong> into a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ml or \u003Cstrong>(b)(4)\u003C\u002Fstrong> ml final container. Your firm failed to validate the time limit the \u003Cstrong>(b)(4)\u003C\u002Fstrong> can be stored in such a manner without negatively impacting the final product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>13. Failure to routinely calibrate, inspect or check automatic, mechanical or electronic equipment or other types of equipment, including computers, or related systems that will perform a function satisfactorily, that are used in the manufacture, processing, packing and holding of a drug product, according to a written program designed to assure proper performance [21 CFR 211.68(a)].\u003C\u002Fstrong> Specifically, you failed to validate the software used to maintain your sterility testing results according to a written program designed to assure the software’s proper performance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>14. Failure to assign and label each HCT\u002FP that you manufacture with a distinct identification code in accordance with the requirements in 21 CFR 1271.290(c).\u003C\u002Fstrong> Specifically, you do not ensure that each HCT\u002FP that you manufacture is assigned and labeled with a distinct identification code that relates the HCT\u002FP to the donor and to all records pertaining to the HCT\u002FP and that labeling includes information designed to facilitate effective tracking, using the distinct identification code, from the donor to the recipient and from the recipient to the donor.\u003C\u002Fp>\n\n\u003Cp>FDA received your written responses, dated March 5 and April 16, 2021, to the inspectional observations on the Form FDA 483 issued at the conclusion of the inspection, and we have reviewed the contents. FDA acknowledges your commitment to voluntarily cease the manufacture and processing of new HCT\u002FPs until your third-party consultant has reviewed and audited your firm’s processes and procedures. We also acknowledge your commitment to not distribute HCT\u002FPs that remain in inventory until they have been resampled and retested for contamination. These commitments, along with the corrective actions described in the rest of your response, are not adequate to address the above-noted violations.\u003C\u002Fp>\n\n\u003Cp>Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA 483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facilities. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements for biological products, contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf at (313) 393-2034 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nKarlton Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations - Division 2\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> This letter does not pertain to HCT\u002FPs intended for autologous use or allogeneic use in a first-degree or second-degree blood relative. Accordingly, references in this letter to “HCT\u002FPs” or “your products” do not include products you manufacture that are intended for autologous use or allogeneic use in a first-degree or second-degree blood relative. FDA issued a separate Warning Letter to you, dated May 11, 2021, that pertains to those HCT\u002FPs.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nEliott D. Spencer, PhD\n\nRecipient Title\n\nOwner\u002FPresident\n\nUtah Cord Bank LLC dba Utah Cell Bank\n\n8675 S. Sandy Parkway, Suite 110\n\nSandy, UT 84070-6418\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations - Division 2\n\nUnited States\n\nWARNING LETTER\n\nAugust 10, 2021\n\nWarning Letter #OBPO 21-614013\n\nDear Dr. Spencer:\n\nDuring an inspection of your firms, Utah Cord Bank LLC (Utah Cord Bank), dba Utah Cell Bank, and FIOR Bioscience LLC (FIOR Bioscience), co-located at 8675 S. Sandy Parkway, Suite 110, Sandy, UT 84070, conducted between February 1 and February 11, 2021, United States Food and Drug Administration (FDA) investigators documented that you manufacture cellular products for allogeneic use, including: human umbilical cord blood, umbilical cord, and amniotic membrane derived cellular products with the brand names StemVive® and StemMaxx™ (also known as Stemii and Stemshot); a human umbilical cord blood derived product with the brand name StemTru™; and a human umbilical cord derived product with the brand name StemCellect™ (collectively, “your products”).1 FIOR Bioscience distributes your products directly to health care professionals and medical facilities. These products are intended for injection and are purported to be sterile.\n\nInformation and records gathered prior to and at the time of the inspection, including information on the FIOR Bioscience website, https:\u002F\u002Ffiorbio.com reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nYour products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264].\n\nHCT\u002FPs that do not meet all the criteria set forth in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nYour establishments do not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all the criteria in 21 CFR 1271.10(a). Therefore, your products are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\n\nSpecifically, an HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” StemVive® and StemMaxx™ are not intended to perform the same basic function or functions of umbilical cord blood, umbilical cord, or amniotic membrane in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system (for cord blood); serving as a conduit (for umbilical cord); or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, using these products to treat orthopedic conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\n\nIn addition, your products fail to meet other criteria set forth in 21 CFR 1271.10(a). For example, StemVive®, StemMaxx™, and StemTru™ fail to meet 21 CFR 1271.10(a)(4). These cellular products, manufactured at least in part from donated umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use. In addition, StemVive®, StemMaxx™, and StemCellect™ fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord and\u002For amniotic membrane related to their utility for reconstruction, repair, or replacement.\n\nPlease be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210, 211, and 1271.\n\nAt the close of the inspection, the FDA investigators issued a Form FDA 483 to you listing inspectional observations, which described a number of significant deviations from CGMP and CGTP applicable to your products. The deficiencies include, but are not limited to, the following:\n\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. For example:\n\na. Your firm failed to validate the aseptic processes used to manufacture over (b)(4) vials of your StemVive®, StemMaxx™; StemTru™ and StemCellect™ products (i.e., by performing media fill simulations) since your manufacturing operations began. By the nature of their routes of administration, your products purport to be sterile and are expected to be sterile.\n\nb. Your employees use non-sterile personal protective equipment (PPE), for example lab coats, gloves and hair nets, during the manufacture of your products.\n\n2. Failure to have separate or defined areas or such other control systems for your operations as are necessary to prevent contamination or mixups during the course of aseptic processing. [21 CFR 211.42(c)(10)]. For example:\n\na. You allow two or more operators to process product within the same (b)(4). Processing by more than one technician in the same (b)(4) can significantly increase the potential for contamination.\n\nb. Your manufacturing facility is not classified with respect to air quality. The (b)(4), used to process your products, and operator gowning areas are located within an unclassified environment.\n\nc. Your firm has not established an adequate system for monitoring environmental conditions in the aseptic processing area where your products are manufactured.\n\nd. Your firm does not conduct personnel monitoring of operators working in the aseptic processing area where your products are manufactured.\n\ne. Your firm does not have a validated cleaning process for the aseptic processing area where your products are manufactured.\n\n3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example:\n\na. You have not established scientifically sound and appropriate specifications, standards, sampling plans and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity.\n\nb. You do not collect and test sterility samples that are representative of the lot size. You test (b)(4) for sterility and rely on the results of (b)(4) sterility test to determine lot release despite the lot size, which may consist of as many as (b)(4) vials.\n\n4. Failure to include in laboratory records complete data derived from all tests necessary to assure compliance with established specifications and standards, including a statement of each method used in the testing of the sample that indicates the location of data that establish that the methods used in the testing of the sample meet proper standards of accuracy and reliability as applied to the product tested [21 CFR 211.194(a)(2)]. Specifically, lot release of your products is based on sterility testing; however, your in-house sterility test has not been validated. Accordingly, your laboratory records do not include a statement that indicates the location of data that establish that your sterility testing methods meet proper standards of accuracy and reliability as applied to your products.\n\n5. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. Specifically, the manufacturing processes for your products have not been validated.\n\n6. Failure to establish and follow written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, testing, and approval or rejection of components and drug product containers and closures [21 CFR 211.80(a)]. For example:\n\na. There are no written procedures describing in sufficient detail the criteria for approval or rejection of incoming human umbilical cord blood or human umbilical cord.\n\nb. There are no written procedures describing in sufficient detail the acceptance criteria for components used in manufacturing, including (b)(4) micron and (b)(4) micron filters, (b)(4) (glass) bottles, and (b)(4), and drug product containers and closures.\n\n7. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [21 CFR 211.67(b)]. For example:\n\na. Your firm failed to validate the cleaning process for your (b)(4).\n\nb. There are no data or rationale for the cleaning agents used or their rotation for the cleaning of the (b)(4) where manufacturing is performed.\n\nc. Your firm has not established written procedures for the (b)(4) sterilization of the (b)(4) filter and the (b)(4) funnel that come into direct contact with your products during processing.\n\n8. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192]. Specifically, from July 2017 to January 2020, you failed to thoroughly investigate 16 sterility failures. The failed lots were discarded; however, there was no further evaluation to identify the contaminating microorganism, determine a root cause or determine if other product lots may have been affected by the failures.\n\n9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine the appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, you assign a two-to-six year expiration date to your products without supporting data.\n\n10. Failure to establish and follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)]. For example:\n\na. Although your firm received multiple complaints regarding your products, there was no supporting documentation to show that you performed an adequate follow-up and\u002For investigation of those complaints. We note that these complaints were categorized as adverse events on your complaint log.\n\nb. Written procedures describing the handling of all written and oral complaints do not include procedures for review of a complaint to determine whether the complaint represents a serious and\u002For unexpected adverse experience.\n\n11. Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)]. For example:\n\na. Your batch production record does not include documentation of the accomplishment of each significant step in the processing of your products as described in your work instructions. These work instructions include GLP-DOC-0008 entitled “Amniotic Membrane Injectable Product Isolation Processing Work Instruction”; GLP-DOC-0009, Revision 01 entitled “Cord Tissue and Blood Injectable Product Isolation Processing Work Instruction”; and GLP-DOC-010 entitled “Cord Tissue Flowable Product Isolation Processing Work Instruction.”\n\nb. The batch production record does not include documentation of the identity of each batch of component or in-process material used in the processing of your products.\n\nc. The batch production record does not consistently document the results of product sterility testing.\n\nd. The batch production record does not include a statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing (i.e., the quantity of vials produced in each product lot).\n\n12. Failure to establish, when appropriate, time limits for the completion of each phase of production to assure the quality of the drug product [21 CFR 211.111]. Specifically, your firm stores (b)(4) product ((b)(4)) in a (b)(4) ml glass container in a commercial refrigerator in your unclassified lab area for up to (b)(4) prior to aliquoting the (b)(4) into a (b)(4) ml or (b)(4) ml final container. Your firm failed to validate the time limit the (b)(4) can be stored in such a manner without negatively impacting the final product.\n\n13. Failure to routinely calibrate, inspect or check automatic, mechanical or electronic equipment or other types of equipment, including computers, or related systems that will perform a function satisfactorily, that are used in the manufacture, processing, packing and holding of a drug product, according to a written program designed to assure proper performance [21 CFR 211.68(a)]. Specifically, you failed to validate the software used to maintain your sterility testing results according to a written program designed to assure the software’s proper performance.\n\n14. Failure to assign and label each HCT\u002FP that you manufacture with a distinct identification code in accordance with the requirements in 21 CFR 1271.290(c). Specifically, you do not ensure that each HCT\u002FP that you manufacture is assigned and labeled with a distinct identification code that relates the HCT\u002FP to the donor and to all records pertaining to the HCT\u002FP and that labeling includes information designed to facilitate effective tracking, using the distinct identification code, from the donor to the recipient and from the recipient to the donor.\n\nFDA received your written responses, dated March 5 and April 16, 2021, to the inspectional observations on the Form FDA 483 issued at the conclusion of the inspection, and we have reviewed the contents. FDA acknowledges your commitment to voluntarily cease the manufacture and processing of new HCT\u002FPs until your third-party consultant has reviewed and audited your firm’s processes and procedures. We also acknowledge your commitment to not distribute HCT\u002FPs that remain in inventory until they have been resampled and retested for contamination. These commitments, along with the corrective actions described in the rest of your response, are not adequate to address the above-noted violations.\n\nYour response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nNeither this letter nor the observations noted on the Form FDA 483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facilities. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements for biological products, contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf at (313) 393-2034 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations - Division 2\n\n______________________________\n\n1 This letter does not pertain to HCT\u002FPs intended for autologous use or allogeneic use in a first-degree or second-degree blood relative. Accordingly, references in this letter to “HCT\u002FPs” or “your products” do not include products you manufacture that are intended for autologous use or allogeneic use in a first-degree or second-degree blood relative. FDA issued a separate Warning Letter to you, dated May 11, 2021, that pertains to those HCT\u002FPs.","Utah Cord Bank LLC dba Utah Cell Bank","utah-cord-bank-llc-dba-utah-cell-bank-614013-08102021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Futah-cord-bank-llc-dba-utah-cell-bank-614013-08102021","2026-10-26T08:10:18.765289+00:00","2021-08-17","614013","Eliott D. Spencer, PhD","2026-08-20T02:41:41.014+00:00","2021-08-10",{"id":122,"raw":123,"subject":41,"body_html":128,"body_text":129,"firm_name":130,"letter_id":131,"created_at":132,"fei_number":20,"letter_url":133,"updated_at":134,"action_type":23,"case_status":49,"posted_date":135,"marcs_cms_no":136,"product_type":52,"closeout_date":20,"issuing_office":77,"recipient_name":137,"body_fetched_at":138,"delivery_method":80,"recipient_title":20,"reference_number":20,"action_taken_date":139,"medical_device_id":20,"response_letter_date":20},1979,[124,125,126,127,40,13,13,13],"\u003Ctime datetime=\"2023-07-25T13:20:00Z\">07\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-05T04:00:00Z\">06\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023\">Stratus Biosystems, LLC dba CellGenuity Regenerative Science\u003C\u002Fa>"," Division of Biological Products Operations II","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jon D. Tryggestad\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer and Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Stratus Biosystems, LLC dba CellGenuity Regenerative Science\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>913 S Main St Ste 215\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grapevine\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76051-7575\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Biological Products Operations II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 5, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter #OBPO 23-631303\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Lisa Sooter\u003Cbr>\nGeneral Counsel and Co-Owner\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Tryggestad and Ms. Sooter:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Stratus Biosystems, LLC (dba CellGenuity Regenerative Science or CellGenuity), located at 913 S Main St, Ste 215, Grapevine, TX 76051-7575, conducted between October 26, 2021 and November 10, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of products for allogeneic use, including an umbilical cord and amniotic membrane derived product, AmnioAMP-WJ™, and an amniotic fluid derived product, AmnioAllograft (collectively, “your products”).\u003Csup>\u003Cem>\u003Cstrong>1,2,3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You distribute your products to healthcare providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered at the time of and after the inspection, including information regarding your products available online at cellgenuity.com, reflect that your products are intended to treat various diseases or conditions.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your product derived from both umbilical cord and amniotic membrane, AmnioAMP-WJ™, is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Based on a review of materials described above, Stratus Biosystems, LLC does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FP derived from umbilical cord and amniotic membrane fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>Specifically, an HCT\u002FP meets the criterion established by 21 CFR 1271.10(a)(2) if it is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” AmnioAMP-WJ™ is not intended to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, using your product to treat orthopedic diseases or conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>Be advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&amp;C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your product derived from amniotic fluid, AmnioAllograft™, is regulated as a drug and biological product under section 351 of the PHS Act and the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>To lawfully market a drug that is a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved BLA nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during inspection, as discussed below. These deviations, involving over \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of your products manufactured since March 2019, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. \u003C\u002Fstrong>For example:\u003C\u002Fp>\n\n\u003Cp>a. The aseptic processes used to manufacture your products have not been validated (i.e., by performing media fill simulations). By the nature of their routes of administration, your products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\n\n\u003Cp>b. You have not established appropriate written procedures for environmental monitoring in the aseptic processing areas where your products are manufactured. For example, you do not have written procedures that require surface sampling, personnel monitoring, viable air monitoring, and non-viable particulate monitoring to be performed in association with each production run. Such procedures are important to detect problems and demonstrate control of the aseptic processing areas.\u003C\u002Fp>\n\n\u003Cp>c. Your written gowning procedure for personnel who perform aseptic processing is inadequate to protect your products from contamination. For example, in accordance with your written procedure:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. Personnel wear non-sterile gowning components, such as surgical masks and hairnets, while processing your products without any barrier between open products and personnel. Additionally, during the inspection, FDA investigators observed a technician with exposed skin processing your products.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. Personnel don gowning in the unclassified shipping and receiving room prior to entering the cleanroom, which may increase the risk of introducing product contaminants.\u003C\u002Fp>\n\n\u003Cp>d. You have not established and followed written procedures for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filter that comes into direct contact with your AmnioAllograft and AmnioAMP-WJ products during processing.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>2. Failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not validated your process for cleaning and disinfecting the cleanrooms, the critical processing areas where your products are manufactured.\u003C\u002Fp>\n\n\u003Cp>b. According to your Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance”, your cleanrooms require cleaning with a \u003Cstrong>(b)(4)\u003C\u002Fstrong> only \u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong>-forming microorganisms are routinely detected in your environmental samples.\u003C\u002Fp>\n\n\u003Cp>c. Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance” lacks adequate instructions for cleaning and disinfection of your cleanrooms, including the disinfectant contact time and cleaning agents used. Additionally, this procedure does not require cleaning \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacture of batches nor is there data or rationale for the cleaning agents used.\u003C\u002Fp>\n\n\u003Cp>d. Your SOP SB-027 titled “Equipment Management and Cleaning” lacks adequate cleaning procedures for the equipment (e.g., incubators) used during aseptic processing operations, including but not limited to, use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> agent, frequency of disinfectants used, and disinfectant contact times. Additionally, this procedure does not address cleaning between batches.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> For example, you have not established scientifically sound and appropriate specifications and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing and endotoxin testing as measurements of product attributes.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. The manufacturing processes for your products have not been validated with respect to identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>b. Prior to June 2021, you had not established written procedures for manufacturing AmnioAllograft™ or AmnioAMP-WJ™.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed, [21 CFR 211.192].\u003C\u002Fstrong> For example, you failed to thoroughly investigate the following sterility and environmental monitoring failures:\u003C\u002Fp>\n\n\u003Cp>a. From January 2021 and November 2021, your firm has had approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility failures and \u003Cstrong>(b)(4)\u003C\u002Fstrong> endotoxin failures; however, you did not conduct any investigations to determine root cause or determine if any other product lots\u002Fbatches were affected by the failures. Examples of organisms identified in the sterility failures include&nbsp;\u003Cem>Cutibacterium acnes, Staphylococcus pasteuri,\u003C\u002Fem> and \u003Cem>Corynebacterium acnes.\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>b. From July 2021 and August 2021, your firm has had approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> environmental monitoring failures in your critical processing areas where your products are manufactured. While you identified the contaminating organisms, you failed to provide evidence that you investigated these failures to determine the root cause, product impact, or corrective and preventative actions. Examples of organisms identified in your critical processing areas include \u003Cem>Bacillus\u003C\u002Fem> species \u003Cem>non-anthracis, Paenbacillus\u003C\u002Fem> species, and fungi.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, you assigned a \u003Cstrong>(b)(4)\u003C\u002Fstrong>- to \u003Cstrong>(b)(4)\u003C\u002Fstrong>-year expiration date to your products without stability testing.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response, dated December 2, 2021, to FDA’s inspectional observations on the FDA-483 and have determined your response is inadequate to address the above-noted deficiencies. We acknowledge that you represent that “Stratus has stopped manufacture of products until such time as the FDA inspector observations can be addressed.” We also acknowledge your statement that Stratus “has responded to the facts cited in the observation and formulated its plans for action upon the most similar applicable rules under 21 CFR 1271 et seq.”\u003C\u002Fp>\n\n\u003Cp>While you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is also a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect for that product, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Your response also does not address the quantity of product inventory you may still have at your facility and your plans for its disposition. Furthermore, your response does not describe actions you have taken or plan to take to address the impact of the above-noted CGMP deficiencies on your distributed products that carry a \u003Cstrong>(b)(4)\u003C\u002Fstrong>- to \u003Cstrong>(b)(4)\u003C\u002Fstrong>-year shelf life and were manufactured under the above-described conditions.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure full compliance with the law.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Sam Labinjo, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations, Division 2, 550 W. Jackson, Chicago, IL 66061 or emailed to Samuel.Labinjo@fda.hhs.gov. If you have any questions, please contact Mr. Labinjo at (312) 596-4254 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Your products or similar products were previously marketed under different names as follows: AmnioAllograft (previously AmnioAMP-PF) and AmnioAMP-WJ™ (previously AmnioAMP-EXS and Suspension EXS).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> You also manufactured and marketed amniotic membrane derived products, AmnioAMP-EXS-P and AmnioAMP-X. Based on the information provided, Amnio-EXS-P appeared to be intended to treat immunological diseases or conditions, and AmnioAMP-X appeared to be intended to treat orthopedic diseases or conditions. Such uses are not considered homologous use of amniotic membrane. It appears that these or similar products are currently marketed as AmnioAMP-WJ-P™ and Suspension Allograft, respectively. (AmnioAMP-X also appears the same or similar to amniotic membrane products, Suspension Sports Medicine and Suspension Spine.) Your amniotic membrane derived products must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Additionally, you manufacture a product derived from umbilical cord blood, Progenitor Cell Stem Cells (PCSC). Please be advised that PCSC must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This product or a similar product was previously marketed as CBX.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> For example, AmnioAMP-WJ™ and AmnioAllograft are marketed on your website as being made using your propriety PūrAMP process. Your website states, “PūRAMP PROCESSING preserves the products that can be used in a wide range of surgical and non-surgical applications.” This same webpage states, “PūrAMP SOLUTIONS DESIGNED FOR BROAD APPLICATIONS…NEURO\u002FSPINE…ORTHOPEDICS…CARDIAC…ONCOLOGY… NERVES…”\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJon D. Tryggestad\n\nRecipient Title\n\nChief Executive Officer and Co-Owner\n\nStratus Biosystems, LLC dba CellGenuity Regenerative Science\n\n913 S Main St Ste 215\n\nGrapevine, TX 76051-7575\n\nUnited States\n\nIssuing Office:\n\nDivision of Biological Products Operations II\n\nUnited States\n\nWARNING LETTER\n\nJune 5, 2023\n\nWarning Letter #OBPO 23-631303\n\nLisa Sooter\n\nGeneral Counsel and Co-Owner\n\nDear Mr. Tryggestad and Ms. Sooter:\n\nDuring an inspection of your firm, Stratus Biosystems, LLC (dba CellGenuity Regenerative Science or CellGenuity), located at 913 S Main St, Ste 215, Grapevine, TX 76051-7575, conducted between October 26, 2021 and November 10, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of products for allogeneic use, including an umbilical cord and amniotic membrane derived product, AmnioAMP-WJ™, and an amniotic fluid derived product, AmnioAllograft (collectively, “your products”).1,2,3 You distribute your products to healthcare providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\n\nInformation and records gathered at the time of and after the inspection, including information regarding your products available online at cellgenuity.com, reflect that your products are intended to treat various diseases or conditions.4 Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nYour product derived from both umbilical cord and amniotic membrane, AmnioAMP-WJ™, is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBased on a review of materials described above, Stratus Biosystems, LLC does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FP derived from umbilical cord and amniotic membrane fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\n\nSpecifically, an HCT\u002FP meets the criterion established by 21 CFR 1271.10(a)(2) if it is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” AmnioAMP-WJ™ is not intended to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, using your product to treat orthopedic diseases or conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\n\nBe advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your product derived from amniotic fluid, AmnioAllograft™, is regulated as a drug and biological product under section 351 of the PHS Act and the FD&C Act.\n\nTo lawfully market a drug that is a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved BLA nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210 and 211.\n\nAt the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during inspection, as discussed below. These deviations, involving over (b)(4) vials of your products manufactured since March 2019, include, but are not limited to, the following:\n\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. For example:\n\na. The aseptic processes used to manufacture your products have not been validated (i.e., by performing media fill simulations). By the nature of their routes of administration, your products purport to be sterile and are expected to be sterile.\n\nb. You have not established appropriate written procedures for environmental monitoring in the aseptic processing areas where your products are manufactured. For example, you do not have written procedures that require surface sampling, personnel monitoring, viable air monitoring, and non-viable particulate monitoring to be performed in association with each production run. Such procedures are important to detect problems and demonstrate control of the aseptic processing areas.\n\nc. Your written gowning procedure for personnel who perform aseptic processing is inadequate to protect your products from contamination. For example, in accordance with your written procedure:\n\ni. Personnel wear non-sterile gowning components, such as surgical masks and hairnets, while processing your products without any barrier between open products and personnel. Additionally, during the inspection, FDA investigators observed a technician with exposed skin processing your products.\n\nii. Personnel don gowning in the unclassified shipping and receiving room prior to entering the cleanroom, which may increase the risk of introducing product contaminants.\n\nd. You have not established and followed written procedures for the (b)(4) sterilization of the (b)(4) filter that comes into direct contact with your AmnioAllograft and AmnioAMP-WJ products during processing.\n\n2. Failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)]. For example:\n\na. You have not validated your process for cleaning and disinfecting the cleanrooms, the critical processing areas where your products are manufactured.\n\nb. According to your Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance”, your cleanrooms require cleaning with a (b)(4) only (b)(4). (b)(4)-forming microorganisms are routinely detected in your environmental samples.\n\nc. Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance” lacks adequate instructions for cleaning and disinfection of your cleanrooms, including the disinfectant contact time and cleaning agents used. Additionally, this procedure does not require cleaning (b)(4) manufacture of batches nor is there data or rationale for the cleaning agents used.\n\nd. Your SOP SB-027 titled “Equipment Management and Cleaning” lacks adequate cleaning procedures for the equipment (e.g., incubators) used during aseptic processing operations, including but not limited to, use of a (b)(4) agent, frequency of disinfectants used, and disinfectant contact times. Additionally, this procedure does not address cleaning between batches.\n\n3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example, you have not established scientifically sound and appropriate specifications and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing and endotoxin testing as measurements of product attributes.\n\n4. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example:\n\na. The manufacturing processes for your products have not been validated with respect to identity, strength, quality, and purity.\n\nb. Prior to June 2021, you had not established written procedures for manufacturing AmnioAllograft™ or AmnioAMP-WJ™.\n\n5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed, [21 CFR 211.192]. For example, you failed to thoroughly investigate the following sterility and environmental monitoring failures:\n\na. From January 2021 and November 2021, your firm has had approximately (b)(4) sterility failures and (b)(4) endotoxin failures; however, you did not conduct any investigations to determine root cause or determine if any other product lots\u002Fbatches were affected by the failures. Examples of organisms identified in the sterility failures include Cutibacterium acnes, Staphylococcus pasteuri, and Corynebacterium acnes.\n\nb. From July 2021 and August 2021, your firm has had approximately (b)(4) environmental monitoring failures in your critical processing areas where your products are manufactured. While you identified the contaminating organisms, you failed to provide evidence that you investigated these failures to determine the root cause, product impact, or corrective and preventative actions. Examples of organisms identified in your critical processing areas include Bacillus species non-anthracis, Paenbacillus species, and fungi.\n\n6. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, you assigned a (b)(4)- to (b)(4)-year expiration date to your products without stability testing.\n\nWe have reviewed your written response, dated December 2, 2021, to FDA’s inspectional observations on the FDA-483 and have determined your response is inadequate to address the above-noted deficiencies. We acknowledge that you represent that “Stratus has stopped manufacture of products until such time as the FDA inspector observations can be addressed.” We also acknowledge your statement that Stratus “has responded to the facts cited in the observation and formulated its plans for action upon the most similar applicable rules under 21 CFR 1271 et seq.”\n\nWhile you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is also a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect for that product, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nYour response also does not address the quantity of product inventory you may still have at your facility and your plans for its disposition. Furthermore, your response does not describe actions you have taken or plan to take to address the impact of the above-noted CGMP deficiencies on your distributed products that carry a (b)(4)- to (b)(4)-year shelf life and were manufactured under the above-described conditions.\n\nNeither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure full compliance with the law.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Sam Labinjo, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations, Division 2, 550 W. Jackson, Chicago, IL 66061 or emailed to Samuel.Labinjo@fda.hhs.gov. If you have any questions, please contact Mr. Labinjo at (312) 596-4254 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\n______________________________\n\n1 Your products or similar products were previously marketed under different names as follows: AmnioAllograft (previously AmnioAMP-PF) and AmnioAMP-WJ™ (previously AmnioAMP-EXS and Suspension EXS).\n\n2 You also manufactured and marketed amniotic membrane derived products, AmnioAMP-EXS-P and AmnioAMP-X. Based on the information provided, Amnio-EXS-P appeared to be intended to treat immunological diseases or conditions, and AmnioAMP-X appeared to be intended to treat orthopedic diseases or conditions. Such uses are not considered homologous use of amniotic membrane. It appears that these or similar products are currently marketed as AmnioAMP-WJ-P™ and Suspension Allograft, respectively. (AmnioAMP-X also appears the same or similar to amniotic membrane products, Suspension Sports Medicine and Suspension Spine.) Your amniotic membrane derived products must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271.\n\n3 Additionally, you manufacture a product derived from umbilical cord blood, Progenitor Cell Stem Cells (PCSC). Please be advised that PCSC must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This product or a similar product was previously marketed as CBX.\n\n4 For example, AmnioAMP-WJ™ and AmnioAllograft are marketed on your website as being made using your propriety PūrAMP process. Your website states, “PūRAMP PROCESSING preserves the products that can be used in a wide range of surgical and non-surgical applications.” This same webpage states, “PūrAMP SOLUTIONS DESIGNED FOR BROAD APPLICATIONS…NEURO\u002FSPINE…ORTHOPEDICS…CARDIAC…ONCOLOGY… NERVES…”","Stratus Biosystems, LLC dba CellGenuity Regenerative Science","stratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023","2026-10-26T08:10:06.541654+00:00","2023-07-25","631303","Jon D. Tryggestad","2026-08-20T00:51:52.85+00:00","2023-06-05",6,{"510k":142,"classification":143,"enforcement":144,"event":145,"event_backfill":146,"pma":147,"warning_letter":148},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-20T04:00:32.497+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]